 Berenice Gitomer
Concepts (165)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Polycystic Kidney, Autosomal Dominant | 34 | 2024 | 254 | 6.260 |
Why?
| | Glomerular Filtration Rate | 13 | 2024 | 711 | 1.880 |
Why?
| | Kidney | 16 | 2024 | 1385 | 1.530 |
Why?
| | Kidney Failure, Chronic | 4 | 2020 | 547 | 1.230 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2023 | 430 | 0.810 |
Why?
| | Bone Diseases | 1 | 2020 | 57 | 0.670 |
Why?
| | TRPP Cation Channels | 8 | 2022 | 79 | 0.590 |
Why?
| | Hypertension | 2 | 2018 | 1242 | 0.580 |
Why?
| | Disease Progression | 15 | 2023 | 2635 | 0.570 |
Why?
| | Death | 1 | 2018 | 121 | 0.550 |
Why?
| | Pravastatin | 4 | 2023 | 40 | 0.490 |
Why?
| | Vascular Stiffness | 4 | 2023 | 467 | 0.400 |
Why?
| | Metformin | 2 | 2024 | 315 | 0.310 |
Why?
| | Young Adult | 11 | 2024 | 12426 | 0.310 |
Why?
| | Polycystic Kidney Diseases | 2 | 2023 | 68 | 0.300 |
Why?
| | Adult | 18 | 2024 | 35576 | 0.280 |
Why?
| | Cysts | 2 | 2024 | 109 | 0.280 |
Why?
| | Energy Metabolism | 2 | 2024 | 874 | 0.270 |
Why?
| | Blood Vessels | 2 | 2019 | 187 | 0.270 |
Why?
| | Double-Blind Method | 4 | 2023 | 1876 | 0.240 |
Why?
| | Kaplan-Meier Estimate | 2 | 2018 | 857 | 0.230 |
Why?
| | Biomarkers | 5 | 2024 | 3973 | 0.230 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 2 | 2024 | 42 | 0.230 |
Why?
| | Tryptophan | 2 | 2023 | 179 | 0.230 |
Why?
| | Creatinine | 3 | 2022 | 491 | 0.210 |
Why?
| | Kidney Tubules | 1 | 2024 | 114 | 0.210 |
Why?
| | Longitudinal Studies | 4 | 2020 | 2717 | 0.210 |
Why?
| | Organ Size | 4 | 2017 | 447 | 0.210 |
Why?
| | Endothelium, Vascular | 2 | 2021 | 901 | 0.210 |
Why?
| | Time Factors | 6 | 2022 | 6556 | 0.210 |
Why?
| | Caloric Restriction | 1 | 2024 | 111 | 0.200 |
Why?
| | Humans | 32 | 2024 | 129650 | 0.200 |
Why?
| | Male | 21 | 2024 | 63681 | 0.190 |
Why?
| | Curcumin | 1 | 2021 | 29 | 0.180 |
Why?
| | Child | 9 | 2023 | 20883 | 0.180 |
Why?
| | Metabolome | 2 | 2022 | 338 | 0.180 |
Why?
| | Cross-Sectional Studies | 5 | 2024 | 5066 | 0.180 |
Why?
| | Female | 20 | 2024 | 68776 | 0.180 |
Why?
| | Minerals | 1 | 2020 | 41 | 0.170 |
Why?
| | Dementia | 1 | 2023 | 227 | 0.160 |
Why?
| | Uric Acid | 1 | 2021 | 161 | 0.160 |
Why?
| | Overweight | 2 | 2021 | 531 | 0.160 |
Why?
| | Metabolomics | 2 | 2022 | 652 | 0.160 |
Why?
| | Vascular Diseases | 1 | 2021 | 241 | 0.160 |
Why?
| | Pilot Projects | 1 | 2024 | 1587 | 0.150 |
Why?
| | Spironolactone | 1 | 2019 | 30 | 0.150 |
Why?
| | Mutation | 5 | 2022 | 3717 | 0.150 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2019 | 46 | 0.150 |
Why?
| | Genotype | 3 | 2020 | 1839 | 0.150 |
Why?
| | Fathers | 1 | 2018 | 49 | 0.140 |
Why?
| | Adaptive Immunity | 1 | 2018 | 161 | 0.140 |
Why?
| | Adolescent | 8 | 2021 | 20393 | 0.130 |
Why?
| | Obesity | 2 | 2021 | 2883 | 0.130 |
Why?
| | Fibroblast Growth Factors | 1 | 2017 | 170 | 0.130 |
Why?
| | Prenatal Diagnosis | 1 | 2016 | 190 | 0.120 |
Why?
| | Mice | 6 | 2023 | 16937 | 0.120 |
Why?
| | Age of Onset | 1 | 2016 | 496 | 0.120 |
Why?
| | Oxidative Stress | 2 | 2018 | 1269 | 0.110 |
Why?
| | Linoleic Acids, Conjugated | 1 | 2013 | 8 | 0.110 |
Why?
| | Severity of Illness Index | 2 | 2020 | 2742 | 0.110 |
Why?
| | Lovastatin | 1 | 2013 | 37 | 0.110 |
Why?
| | Survival Rate | 1 | 2018 | 1877 | 0.110 |
Why?
| | Middle Aged | 9 | 2024 | 31154 | 0.100 |
Why?
| | Case-Control Studies | 2 | 2021 | 3381 | 0.100 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2018 | 857 | 0.100 |
Why?
| | Sex Factors | 1 | 2018 | 1968 | 0.100 |
Why?
| | Kynurenine | 2 | 2023 | 114 | 0.090 |
Why?
| | Mothers | 1 | 2018 | 729 | 0.090 |
Why?
| | Disease Models, Animal | 3 | 2022 | 4063 | 0.090 |
Why?
| | Prospective Studies | 5 | 2021 | 7133 | 0.090 |
Why?
| | Animals | 7 | 2023 | 35361 | 0.090 |
Why?
| | Retrospective Studies | 2 | 2018 | 14518 | 0.080 |
Why?
| | Databases, Factual | 1 | 2015 | 1269 | 0.080 |
Why?
| | Heart Ventricles | 1 | 2014 | 781 | 0.080 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2010 | 375 | 0.080 |
Why?
| | Mice, Inbred C57BL | 4 | 2023 | 5440 | 0.070 |
Why?
| | Receptors, Interleukin-8B | 1 | 2008 | 24 | 0.070 |
Why?
| | Cyst Fluid | 1 | 2008 | 26 | 0.070 |
Why?
| | Practice Guidelines as Topic | 1 | 2015 | 1501 | 0.070 |
Why?
| | Interleukin-8 | 1 | 2008 | 262 | 0.070 |
Why?
| | Inflammation | 3 | 2022 | 2736 | 0.060 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2010 | 2073 | 0.060 |
Why?
| | Infant, Newborn | 1 | 2016 | 5762 | 0.060 |
Why?
| | Liver Diseases | 1 | 2008 | 290 | 0.060 |
Why?
| | Cardiovascular Diseases | 1 | 2017 | 2004 | 0.060 |
Why?
| | Chitinase-3-Like Protein 1 | 1 | 2024 | 19 | 0.060 |
Why?
| | Blood Pressure | 2 | 2023 | 1736 | 0.060 |
Why?
| | Lipocalin-2 | 1 | 2024 | 75 | 0.060 |
Why?
| | Fatty Acid-Binding Proteins | 1 | 2024 | 69 | 0.050 |
Why?
| | Chemokine CCL2 | 1 | 2024 | 118 | 0.050 |
Why?
| | B7-1 Antigen | 1 | 2023 | 61 | 0.050 |
Why?
| | Hypercapnia | 1 | 2023 | 50 | 0.050 |
Why?
| | Tryptophan Oxygenase | 1 | 2023 | 35 | 0.050 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2023 | 56 | 0.050 |
Why?
| | Infant | 1 | 2016 | 9024 | 0.050 |
Why?
| | Blood Flow Velocity | 1 | 2023 | 404 | 0.050 |
Why?
| | Endocannabinoids | 1 | 2022 | 53 | 0.050 |
Why?
| | Mice, Mutant Strains | 1 | 2022 | 298 | 0.050 |
Why?
| | B7-H1 Antigen | 1 | 2023 | 196 | 0.050 |
Why?
| | Databases, Genetic | 1 | 2022 | 232 | 0.040 |
Why?
| | Mice, Knockout | 2 | 2023 | 2871 | 0.040 |
Why?
| | Cell Proliferation | 1 | 2008 | 2391 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2023 | 1206 | 0.040 |
Why?
| | Liver | 1 | 2008 | 1839 | 0.040 |
Why?
| | Mosaicism | 1 | 2019 | 71 | 0.040 |
Why?
| | Aged | 1 | 2018 | 22103 | 0.040 |
Why?
| | Phenotype | 2 | 2022 | 3076 | 0.040 |
Why?
| | Tandem Mass Spectrometry | 1 | 2022 | 524 | 0.040 |
Why?
| | Cell Line | 2 | 2018 | 2781 | 0.040 |
Why?
| | Treatment Outcome | 3 | 2021 | 10230 | 0.040 |
Why?
| | Epithelial Cells | 2 | 2018 | 1065 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2021 | 868 | 0.040 |
Why?
| | Pulse Wave Analysis | 1 | 2018 | 248 | 0.030 |
Why?
| | Brachial Artery | 1 | 2018 | 192 | 0.030 |
Why?
| | Femoral Artery | 1 | 2018 | 173 | 0.030 |
Why?
| | Carotid Arteries | 1 | 2018 | 196 | 0.030 |
Why?
| | Cohort Studies | 2 | 2021 | 5420 | 0.030 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2018 | 181 | 0.030 |
Why?
| | Chi-Square Distribution | 1 | 2017 | 516 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2019 | 487 | 0.030 |
Why?
| | 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid | 1 | 2015 | 6 | 0.030 |
Why?
| | Linoleic Acids | 1 | 2015 | 7 | 0.030 |
Why?
| | Hydroxyeicosatetraenoic Acids | 1 | 2015 | 42 | 0.030 |
Why?
| | Hypoglycemic Agents | 1 | 2024 | 1220 | 0.030 |
Why?
| | Cognition | 1 | 2023 | 1123 | 0.030 |
Why?
| | Linear Models | 1 | 2017 | 819 | 0.030 |
Why?
| | Odds Ratio | 1 | 2017 | 1023 | 0.030 |
Why?
| | Registries | 1 | 2022 | 1896 | 0.030 |
Why?
| | Up-Regulation | 1 | 2017 | 840 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2017 | 1201 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 2 | 2017 | 3408 | 0.030 |
Why?
| | Immunotherapy | 1 | 2018 | 592 | 0.030 |
Why?
| | Arachidonate 12-Lipoxygenase | 1 | 2013 | 17 | 0.030 |
Why?
| | Arachidonate 15-Lipoxygenase | 1 | 2013 | 23 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2017 | 1502 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2022 | 2282 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2018 | 2119 | 0.030 |
Why?
| | Risk Factors | 2 | 2017 | 9765 | 0.030 |
Why?
| | Albuminuria | 1 | 2014 | 183 | 0.030 |
Why?
| | Consensus | 1 | 2015 | 616 | 0.020 |
Why?
| | Logistic Models | 1 | 2017 | 1988 | 0.020 |
Why?
| | United States | 2 | 2022 | 13903 | 0.020 |
Why?
| | Prognosis | 1 | 2020 | 3794 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2017 | 1368 | 0.020 |
Why?
| | Risk Assessment | 1 | 2020 | 3240 | 0.020 |
Why?
| | Signal Transduction | 2 | 2018 | 4925 | 0.020 |
Why?
| | Quality of Life | 1 | 2022 | 2704 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2022 | 5406 | 0.020 |
Why?
| | Chemokines | 1 | 2010 | 226 | 0.020 |
Why?
| | Body Mass Index | 1 | 2017 | 2273 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2014 | 1952 | 0.020 |
Why?
| | Chemokine CXCL5 | 1 | 2008 | 11 | 0.020 |
Why?
| | Chemokine CXCL1 | 1 | 2008 | 73 | 0.020 |
Why?
| | Cell Shape | 1 | 2008 | 56 | 0.020 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2010 | 399 | 0.020 |
Why?
| | Cell Polarity | 1 | 2008 | 140 | 0.020 |
Why?
| | Cell Hypoxia | 1 | 2008 | 235 | 0.020 |
Why?
| | Stress, Mechanical | 1 | 2008 | 467 | 0.020 |
Why?
| | Transfection | 1 | 2008 | 911 | 0.020 |
Why?
| | Rats | 1 | 2013 | 5500 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 2008 | 1207 | 0.010 |
Why?
| | Endothelial Cells | 1 | 2008 | 749 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 2008 | 1418 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2008 | 3215 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2008 | 4083 | 0.010 |
Why?
|
|
Gitomer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|